ClinicalTrials.gg
CompletedNCT00240799Updated Jun 19, 2015

An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.

A Phase 3 interventional study of acetaminophen extended release and placebo in Osteoarthritis, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-06-19.

Primary conditionOsteoarthritis, HipRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Hip
Why
  1. The study's title name Osteoarthritis, Hip, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Osteoarthritis, Hip by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Osteoarthritis, Hip · Johnson & Johnson.

Enrollment
4th of 10
542 · median 475
Phase 3
9 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Osteoarthritis, Hip by Johnson & Johnson, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 9 in phase 3, and was the 1st registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

None of the 11 studies in Osteoarthritis, Hip by Johnson & Johnson is open now. The open studies under Osteoarthritis, Hip, anywhere →

Who these studies take

Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Osteoarthritis, Hip by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to evaluate acetaminophen extended release (3900 mg/day) compared to placebo for safety and effectiveness in the relief of signs and symptoms of osteoarthritis of the hip or knee over 12 weeks

Read the detailed description

This is a randomized, double-blind, placebo controlled study to evaluate acetaminophen extended release 3900 mg/day compared with placebo in the relief of signs and symptoms of osteoarthritis of the hip or knee over 12 weeks. The hypothesis is that 3900 mg/day acetaminophen extended release is superior to placebo in the relief of signs and symptoms of osteoarthritis of the hip or knee with respect to the three primary effectiveness endpoints. Propoxyphene Hydrochloride Capsules, 65 mg, are used as rescue medication if subjects experience inadequate pain relief. The primary efficacy assessments are the average change from baseline through Week 12 for the WOMAC pain subscale score and the WOMAC physical function subscale score, and the subject's average global assessment of their response to therapy through Week 12. Safety assessments at study visits consist of monitoring adverse events, vital signs, study joint assessments and clinical laboratory determinations. Treatment consists of two acetaminophen 650 mg extended release caplets or two placebo caplets, administered orally every 8 hours for 12 weeks.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • osteoarthritis hip
  • osteoarthritis knee
  • acetaminophen
04

In context

Osteoarthritis, Hip Reclassified

642 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.

This study's enrollment of 542 is above the median of 90 across 458 interventional studies indexed under Osteoarthritis, Hip.

Browse Osteoarthritis, Hip studies →

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.

First submitted before Johnson & Johnson Consumer and Personal Products Worldwide left Johnson & Johnson.

Compared within Osteoarthritis, Hip, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms of osteoarthritis of the hip or knee for a minimum of six months
  • History of hip or knee pain due to osteoarthritis requiring the use of NSAIDs, acetaminophen or another analgesic agent on a regular basis (>= three days/week) for at least three months before the screening visit
  • History of positive benefit with acetaminophen use for osteoarthritis pain
  • History (ie, at any time in the past since diagnosis) of osteoarthritis pain of the hip or knee when not taking osteoarthritis analgesic medication
  • Subjects must report a history of a pain level of moderate, moderately severe, or severe, a WOMAC pain score >= 65 at baseline, and a 20% or greater increase in their pain score relative to their score at screening

Exclusion criteria

Exclusion Criteria:

  • History of surgery, including arthroscopy, or major trauma to the study joint in the previous six months before the screening visit
  • Grade 1 or grade 4 severity of the study joint based on the Kellgren and Lawrence radiographic criteria
  • Signs of active inflammation of the study knee joint including redness, warmth, and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits
  • Secondary osteoarthritis of the study joint including, but not limited to, septic arthritis, inflammatory joint disease, gout, Paget's disease of bone, articular fracture, major dysplasias or congenital abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, avascular necrosis, or primary osteochondromatosis
  • History of acute inflammatory arthritis or pseudogout of the study joint.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
542 participants (actual)

Study arms

  • Experimental
    001

    acetaminophen extended release

    Drug: acetaminophen extended release

  • Placebo comparator
    002

    placebo

    Drug: placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Average change from baseline through Week 12 for WOMAC pain subscale score. Average change from baseline through Week 12 for WOMAC physical function subscale score. Subject's average global assessment of response to therapy through Week 12.

Secondary outcomes

  1. Average change from baseline through Week 12 for: WOMAC stiffness subscale score; total WOMAC Osteoarthritis Index; and Nottingham Health Profile Energy subscale score

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Prior MJ, Harrison DD, Frustaci ME. A randomized, double-blind, placebo-controlled 12 week trial of acetaminophen extended release for the treatment of signs and symptoms of osteoarthritis. Curr Med Res Opin. 2014 Nov;30(11):2377-87. doi: 10.1185/03007995.2014.949646. Epub 2014 Aug 14. PubMed 25121804 ↗
  • Kuffner EK, Temple AR, Cooper KM, Baggish JS, Parenti DL. Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. Curr Med Res Opin. 2006 Nov;22(11):2137-48. doi: 10.1185/030079906x148346. PubMed 17076974 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00240799
Responsible party
Sponsor
First posted
Oct 18, 2005
Completion
Oct 2004
Last update
Jun 19, 2015

Study contacts

McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial
study director · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion